버이오텍놀로지(VIR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.49 (-3.94%), 시가총액 $1.50B, 52주 최저~최고 $4.28 ~ $11.09.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amende
버이오텍놀로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
버이오텍놀로지의 현재 주가는 $10.49 (-3.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
버이오텍놀로지의 시가총액은 약 $1.50B입니다.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and international